Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Endocrine Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(394)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
BRAF V600E
Thyroid Gland Papillary Carcinoma
BRAF V600E
Thyroid Gland Papillary Carcinoma
vemurafenib
Sensitive: C1 - Off-label
J Transl Med - 3 weeks (New D)
vemurafenib
Sensitive
:
C1
J Transl Med - 3wk
vemurafenib
Sensitive: C1 - Off-label
J Transl Med - 3 weeks
vemurafenib
Sensitive
:
C1
J Transl Med - 3 weeks - (New D)
BRAF V600E
Thyroid Gland Papillary Carcinoma
BRAF V600E
Thyroid Gland Papillary Carcinoma
dabrafenib
Sensitive: C1 - Off-label
J Transl Med - 3 weeks (New D)
dabrafenib
Sensitive
:
C1
J Transl Med - 3wk
dabrafenib
Sensitive: C1 - Off-label
J Transl Med - 3 weeks
dabrafenib
Sensitive
:
C1
J Transl Med - 3 weeks - (New D)
No biomarker
Thyroid Gland Medullary Carcinoma
No biomarker
Thyroid Gland Medullary Carcinoma
cabozantinib capsule
Sensitive: A1 - Approval
cabozantinib capsule
Sensitive
:
A1
cabozantinib capsule
Sensitive: A1 - Approval
cabozantinib capsule
Sensitive
:
A1
RET fusion
Thyroid Gland Carcinoma
RET fusion
Thyroid Gland Carcinoma
pralsetinib
Sensitive: A1 - Approval
pralsetinib
Sensitive
:
A1
pralsetinib
Sensitive: A1 - Approval
pralsetinib
Sensitive
:
A1
No biomarker
Thyroid Gland Carcinoma
No biomarker
Thyroid Gland Carcinoma
cabozantinib tablet
Sensitive: A1 - Approval
cabozantinib tablet
Sensitive
:
A1
cabozantinib tablet
Sensitive: A1 - Approval
cabozantinib tablet
Sensitive
:
A1
RET mutation
Thyroid Gland Medullary Carcinoma
RET mutation
Thyroid Gland Medullary Carcinoma
selpercatinib
Sensitive: A1 - Approval
selpercatinib
Sensitive
:
A1
selpercatinib
Sensitive: A1 - Approval
selpercatinib
Sensitive
:
A1
No biomarker
Adrenal Cortex Carcinoma
No biomarker
Adrenal Cortex Carcinoma
mitotane
Sensitive: A1 - Approval
mitotane
Sensitive
:
A1
mitotane
Sensitive: A1 - Approval
mitotane
Sensitive
:
A1
RET fusion
Thyroid Gland Carcinoma
RET fusion
Thyroid Gland Carcinoma
selpercatinib
Sensitive: A1 - Approval
selpercatinib
Sensitive
:
A1
selpercatinib
Sensitive: A1 - Approval
selpercatinib
Sensitive
:
A1
No biomarker
Thyroid Gland Hurthle Cell Carcinoma
No biomarker
Thyroid Gland Hurthle Cell Carcinoma
sorafenib
Sensitive: A1 - Approval
sorafenib
Sensitive
:
A1
sorafenib
Sensitive: A1 - Approval
sorafenib
Sensitive
:
A1
No biomarker
Thyroid Gland Follicular Carcinoma
No biomarker
Thyroid Gland Follicular Carcinoma
sorafenib
Sensitive: A1 - Approval
sorafenib
Sensitive
:
A1
sorafenib
Sensitive: A1 - Approval
sorafenib
Sensitive
:
A1
No biomarker
Thyroid Gland Papillary Carcinoma
No biomarker
Thyroid Gland Papillary Carcinoma
sorafenib
Sensitive: A1 - Approval
sorafenib
Sensitive
:
A1
sorafenib
Sensitive: A1 - Approval
sorafenib
Sensitive
:
A1
No biomarker
Thyroid Gland Follicular Carcinoma
No biomarker
Thyroid Gland Follicular Carcinoma
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
No biomarker
Thyroid Gland Hurthle Cell Carcinoma
No biomarker
Thyroid Gland Hurthle Cell Carcinoma
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
No biomarker
Thyroid Gland Papillary Carcinoma
No biomarker
Thyroid Gland Papillary Carcinoma
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
No biomarker
Thyroid Gland Medullary Carcinoma
No biomarker
Thyroid Gland Medullary Carcinoma
vandetanib
Sensitive: A1 - Approval
vandetanib
Sensitive
:
A1
vandetanib
Sensitive: A1 - Approval
vandetanib
Sensitive
:
A1
BRAF V600E
Thyroid Gland Anaplastic Carcinoma
BRAF V600E
Thyroid Gland Anaplastic Carcinoma
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
RET mutation
Thyroid Gland Medullary Carcinoma
RET mutation
Thyroid Gland Medullary Carcinoma
pralsetinib
Sensitive: A1 - Approval
pralsetinib
Sensitive
:
A1
pralsetinib
Sensitive: A1 - Approval
pralsetinib
Sensitive
:
A1
BRAF V600E
Thyroid Gland Anaplastic Carcinoma
BRAF V600E
Thyroid Gland Anaplastic Carcinoma
dabrafenib
Sensitive: A1 - Approval
dabrafenib
Sensitive
:
A1
dabrafenib
Sensitive: A1 - Approval
dabrafenib
Sensitive
:
A1
No biomarker
Thyroid Gland Carcinoma
No biomarker
Thyroid Gland Carcinoma
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
NTRK1 fusion
Thyroid Gland Follicular Carcinoma
NTRK1 fusion
Thyroid Gland Follicular Carcinoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
No biomarker
Thyroid Gland Medullary Carcinoma
No biomarker
Thyroid Gland Medullary Carcinoma
dacarbazine
Sensitive: A2 - Guideline
dacarbazine
Sensitive
:
A2
dacarbazine
Sensitive: A2 - Guideline
dacarbazine
Sensitive
:
A2
NTRK2 fusion
Thyroid Gland Follicular Carcinoma
NTRK2 fusion
Thyroid Gland Follicular Carcinoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK3 fusion
Thyroid Gland Follicular Carcinoma
NTRK3 fusion
Thyroid Gland Follicular Carcinoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK1 fusion
Thyroid Gland Hurthle Cell Carcinoma
NTRK1 fusion
Thyroid Gland Hurthle Cell Carcinoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK2 fusion
Thyroid Gland Hurthle Cell Carcinoma
NTRK2 fusion
Thyroid Gland Hurthle Cell Carcinoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK1 fusion
Thyroid Gland Follicular Carcinoma
NTRK1 fusion
Thyroid Gland Follicular Carcinoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK2 fusion
Thyroid Gland Follicular Carcinoma
NTRK2 fusion
Thyroid Gland Follicular Carcinoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK3 fusion
Thyroid Gland Follicular Carcinoma
NTRK3 fusion
Thyroid Gland Follicular Carcinoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
No biomarker
Adrenal Cortex Carcinoma
No biomarker
Adrenal Cortex Carcinoma
cisplatin + carboplatin + etoposide IV + mitotane + SGN-15
Sensitive: A2 - Guideline
cisplatin + carboplatin + etoposide IV + mitotane + SGN-15
Sensitive
:
A2
cisplatin + carboplatin + etoposide IV + mitotane + SGN-15
Sensitive: A2 - Guideline
cisplatin + carboplatin + etoposide IV + mitotane + SGN-15
Sensitive
:
A2
No biomarker
Thyroid Gland Anaplastic Carcinoma
No biomarker
Thyroid Gland Anaplastic Carcinoma
CaT
Sensitive: A2 - Guideline
CaT
Sensitive
:
A2
CaT
Sensitive: A2 - Guideline
CaT
Sensitive
:
A2
No biomarker
Adrenal Cortex Carcinoma
No biomarker
Adrenal Cortex Carcinoma
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
No biomarker
Adrenal Cortex Carcinoma
No biomarker
Adrenal Cortex Carcinoma
cisplatin
Sensitive: A2 - Guideline
cisplatin
Sensitive
:
A2
cisplatin
Sensitive: A2 - Guideline
cisplatin
Sensitive
:
A2
NTRK2 fusion
Thyroid Gland Papillary Carcinoma
NTRK2 fusion
Thyroid Gland Papillary Carcinoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
TMB-H
Thyroid Gland Hurthle Cell Carcinoma
TMB-H
Thyroid Gland Hurthle Cell Carcinoma
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login